Subscribe
shutterstock_544602286_jon_bilous
Jon Bilous / Shutterstock.com
5 May 2022Big PharmaAlex Baldwin

Harvard, 10x say Vizgen infringes genomics patents

Harvard College and 10x Genomics have sued Vizgen, claiming that the Massachusetts-based biotech rival infringes five patents covering molecular analysis methods.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Vizgen accuses Harvard and 10x of patent licence cover-up
4 May 2023   Firm says patents-in-suit were developed using $19 million of public money | Biotech also cites “new evidence” in suit with Harvard and 10x.
Biotechnology
10x escalates genomics patents dispute at the UPC
8 June 2023   Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
Harvard and 10x to face anti-competitive claims over genomics patents
13 July 2023   Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Vizgen accuses Harvard and 10x of patent licence cover-up
4 May 2023   Firm says patents-in-suit were developed using $19 million of public money | Biotech also cites “new evidence” in suit with Harvard and 10x.
Biotechnology
10x escalates genomics patents dispute at the UPC
8 June 2023   Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
Harvard and 10x to face anti-competitive claims over genomics patents
13 July 2023   Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.

More on this story

Americas
Vizgen accuses Harvard and 10x of patent licence cover-up
4 May 2023   Firm says patents-in-suit were developed using $19 million of public money | Biotech also cites “new evidence” in suit with Harvard and 10x.
Biotechnology
10x escalates genomics patents dispute at the UPC
8 June 2023   Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
Harvard and 10x to face anti-competitive claims over genomics patents
13 July 2023   Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent